Page last updated: 2024-09-05

lapatinib and apatinib

lapatinib has been researched along with apatinib in 2 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (apatinib)	Trials (apatinib)	Recent Studies (post-2010) (apatinib)
1,919	305	1,442	575	109	544

Protein Interaction Comparison

Protein	Taxonomy	lapatinib (IC50)	apatinib (IC50)
Vascular endothelial growth factor receptor 2	Homo sapiens (human)		0.001

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X	1
Ye, G; Zhang, C; Zhang, J	1

Reviews

1 review(s) available for lapatinib and apatinib

Article	Year
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. The Cochrane database of systematic reviews, 2021, 03-04, Volume: 3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult	2021

Article

Year

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

The Cochrane database of systematic reviews, 2021, 03-04, Volume: 3

Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult

2021

Other Studies

1 other study(ies) available for lapatinib and apatinib

Article	Year
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma. Aging, 2021, 08-30, Volume: 13, Issue:16 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Interferons; Lapatinib; Male; Membrane Proteins; Mice, Inbred BALB C; Nucleotides, Cyclic; Pyridines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Vascular Endothelial Growth Factor Receptor-2; Xanthones; Xenograft Model Antitumor Assays	2021

Article

Year

Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.

Aging, 2021, 08-30, Volume: 13, Issue:16

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Interferons; Lapatinib; Male; Membrane Proteins; Mice, Inbred BALB C; Nucleotides, Cyclic; Pyridines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Vascular Endothelial Growth Factor Receptor-2; Xanthones; Xenograft Model Antitumor Assays

2021